

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- Why both somatic and germline genomic profiling are essential for precision oncology